Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

A Multicomponent Approach to Screening for Dementia in Older Hospitalized Patients

Tan ZS, Qureshi N, Sicotte NL, Hirsch D, Escovedo C, Spivack E, Nasmyth MC, Gonzales M, Kremen SA, Nuckols TK, Mafi J, McFadden J, Roberts[...]

Disparities in Healthcare Seeking and Physician Diagnosis of Irritable Bowel Syndrome: Results from a US Survey

Almario CV, Liu J, Higgins C, Yerneni N, Boules M, Chey WD, Chang L. Disparities in Healthcare Seeking and Physician Diagnosis of Irritable Bowel Syndrome:[...]

Correlates and prognostic value of left atrial strain in transcatheter edge-to-edge repair for degenerative mitral regurgitation

Shechter A, Taheri H, Kaewkes D, Nagasaka T, Suruga K, Gupta A, Patel V, Koren O, Koseki K, Skaf S, Makar M, Patel D, Chakravarty[...]